Back to VRTX Stock Lookup

Vertex Pharma (VRTX) – Company Press Releases

Jul 29, 2015 04:01 PM Vertex Reports Second Quarter 2015 Financial Results
Jul 14, 2015 09:00 AM Vertex to Announce Second Quarter 2015 Financial Results on July 29
Jul 2, 2015 01:46 PM FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation
Jul 2, 2015 01:46 PM ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutat
Jun 18, 2015 04:01 PM Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors
Jun 11, 2015 09:00 AM Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 4, 2015 04:01 PM Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
Jun 3, 2015 04:01 PM Vertex to Present at the Goldman Sachs Healthcare Conference on June 11
May 17, 2015 01:32 PM New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation
May 13, 2015 04:01 PM Vertex to Present at the UBS Healthcare Conference on May 19
May 12, 2015 04:15 PM Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F
Apr 29, 2015 04:01 PM Vertex Reports First Quarter 2015 Financial Results
Apr 9, 2015 04:01 PM Vertex to Announce First Quarter 2015 Financial Results on April 29
Mar 23, 2015 07:45 AM Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation
Mar 18, 2015 07:46 AM Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene

Back to VRTX Stock Lookup